#easd2026
LightNews LightNews
metabolon.bsky.social
What’s the most important unanswered question in diabetes research?

At #EASD2026, Dr. Denise Faustman shared why looking beyond blood glucose matters, and how metabolomics can help resolve the underlying biology.

▶️ Watch her perspective.
October 9, 2026 at 2:28 PM
biomedicines.bsky.social
#EASD2026 came to a successful close! 👏
It was a pleasure to welcome our Editorial Board Member, Dr. Laura Marroquí Esclapez, at our booth! We greatly appreciate her support and valuable contributions & look forward to continuing our collaboration in #Biomedicines!🤝
October 9, 2026 at 3:02 AM
yoshitakahoshi.bsky.social
【CagriSema、高カロリー食の脳の反応が変わり、体重は22.4％減】
Novo Nordisk。過体重または肥満の成人52週で、CagriSemaは高カロリー食品の画像に対する脳の反応を変えた。食への渇望や空腹感の指標が改善し、体重はプラセボより22.4％減った（p＜0.0001）。2型糖尿病の第3相REIMAGINE 1では、腹部、肝臓、膵臓の脂肪が減った。
Novo Nordisk、CagriSemaの新データ発表──脳のfMRIで食欲関連反応を確認、2型糖尿病患者で臓器脂肪と骨指標にも効果示唆
stellanews.life/technology/1...
Novo Nordisk、CagriSemaの新データ発表──脳のfMRIで食欲関連反応を確認、2型糖尿病患者で臓器脂肪と骨指標にも効果示唆
Novo Nordisk社は、開発中の肥満・2型糖尿病治療薬CagriSemaについて、脳機能MRI（fMRI）試験と2件の第3相関連試験の新データをEASD2026で発表した。52週時点で体重がプラセボ比22.4%減少したほか、腹部・肝臓・膵臓の異所性脂肪減少や骨マーカーの維持傾向が報告された。
stellanews.life
October 8, 2026 at 3:28 AM
newsen.bsky.social
SIBIONICS and PharmaSens Discover New Frontiers in Automated Insulin Management at EASD 2026#None#Milano#SIBIONICS#PharmaSens#EASD2026
SIBIONICS and PharmaSens Discover New Frontiers in Automated Insulin Management at EASD 2026
At the 2026 EASD meeting, SIBIONICS unveiled innovative concepts in automated insulin management, promising significant strides in diabetes care.
third-news.com
October 8, 2026 at 2:29 AM
biomedicines.bsky.social
#EASD2026 has wrapped up! 👏
It was a pleasure to meet our Guest Editor, Dr. Tomislav Bulum, at our booth! We appreciate his support and valuable contribution and we look forward to continuing our collaboration and working together! 🤝
#Conference #Biomedicines
October 8, 2026 at 12:16 AM
springermedicine.com
Catch up on the latest advances in #diabetes research, treatment, and care from #EASD2026 with our hub page.

👉️ buff.ly/7GIjfiy

#MedSky
October 6, 2026 at 3:15 PM
sociedadseen.bsky.social
📢 El 8 de octubre, revisaremos los principales avances del #EASD2026 en diabetes: tecnología en DM1 y DM2, nuevas dianas terapéuticas, enfermedad cardiorrenal, obesidad, medicina de precisión y más.

👉 https://f.mtr.cool/coi9c6nas1
October 6, 2026 at 3:02 PM
easdnews.bsky.social
🎥💙 The #EASD2026 Annual Meeting may be over, but the conversations continue.

We asked delegates why they do what they do: 60 seconds each, 1️⃣thing in common: they all want to help people.

🎬👇 Watch "Human Behind Science" & meet the people behind the research.

www.linkedin.com/posts/easd_e...
EASD Entertainment: The Human Behind The Science | European Association for the Study of Diabetes e.V. (EASD)
🎥 💙 The #EASD2026 Annual Meeting may be over, but the conversations continue. At #EASD2026, we asked delegates a simple question: why do you do what you do? In just 60 seconds, researchers, clinician...
www.linkedin.com
October 6, 2026 at 11:35 AM
diabresearch-dzd.bsky.social
🔬 DZD at EASD 2026:A short photo review
Exciting research, inspiring scientific sessions, prestigious awards and many valuable conversations at the DZD booth. Thank you to everyone who visited us and helped make #EASD2026 such a special event!
📸 A short photo review
#DZD #DiabetesResearch
October 6, 2026 at 6:45 AM
springermedicine.com
From #EASD2026 - The long-acting amylin analog petrelintide is well tolerated and can achieve clinically and statistically significant weight loss in people with #obesity compared with placebo.

👉️ buff.ly/BlrCa0G

#MedNews
ZUPREME 1 supports petrelintide therapy for obesity
The long-acting amylin analog petrelintide is well tolerated and can achieve clinically and statistically significant weight loss in people with obesity compared with placebo.
www.springermedicine.com
October 5, 2026 at 10:54 AM
idfe.bsky.social
🙌Last week, at #EASD2026, we brought together PwD, HCPs & other experts to discuss the future of diabetes education in the #AI era.

From digital tools to personalised support, the event sparked interesting reflections on how diabetes education can evolve to better support PwD.
October 5, 2026 at 8:39 AM
midgardfinance.com
💉 #obesity #EASD2026

🇺🇸 #$LLY #retatrutide took off 18.8% in type 2 diabetes, the most of six drugs. 🇩🇪 Boehringer's #survodutide, from 🇩🇰 #$ZEAL: 9.8%, and 26% stopped for side effects. All randomised patients.

All of EASD in one post:
midgardfinance.com/blog/2026/10/04/easd-2026-roundup/
Horizontal bar chart titled "Weight loss with type 2 diabetes": weight lost by adults with obesity and type 2 diabetes on the top dose of six drugs, each beside its own trial's placebo, counting all randomised patients. Retatrutide 12 mg (TRIUMPH-2, 80 weeks): 18.8% against 5.1% on placebo. Tirzepatide 15 mg (SURMOUNT-2, 72 weeks): 14.7% against 3.2% on placebo. CagriSema 2.4/2.4 mg (REDEFINE 2, 68 weeks): 13.7% against 3.4% on placebo. Semaglutide 7.2 mg (STEP UP T2D, 72 weeks): 13.2% against 3.9% on placebo. Survodutide 6.0 mg (SYNCHRONIZE-2, 76 weeks): 9.8% against 3.9% on placebo. Orforglipron 36 mg (ATTAIN-2, 72 weeks): 9.6% against 2.5% on placebo. Retatrutide and survodutide, the two trials read out at the EASD congress, are drawn in purple and the other four in grey. These are separate trials of 68 to 80 weeks, not a head-to-head comparison.
October 5, 2026 at 7:00 AM
easoobesity.bsky.social
EASO was delighted to join colleagues from EASD, ESC and EUDF and welcome EU Health Commissioner Oliver Varhelyi to launch #EUScreeningWeek in Milano at #EASD2026. View the press event: audiovisual.ec.europa.eu/en/media/vid...

Read the press release: easo.org/eu-screening...
October 3, 2026 at 2:49 PM
conscienhealth.bsky.social
At #EASD2026 in Milan this week, a dazzling show of new data on obesity and diabetes fits a broader picture looking beyond weight outcomes to health outcomes.
HT: @elilillyandcompany.bsky.social @novonordisk.bsky.social @regeneron.com @boehringerglobal.bsky.social
conscienhealth.org/2026/10/03/e...
October 3, 2026 at 10:10 AM
easdnews.bsky.social
1️⃣week. 1️⃣ global #diabetes community. 16,000+ delegates! Thank you all for being part of #EASD2026! 🙏

👇 Take one final look at our highlights & look ahead…

🔔 Save the date for #EASD2027 in Budapest! 🇭🇺
📅 20 - 24 Sept 2027 |📍 Hungexpo Budapest Congress Centre

🎥 www.linkedin.com/feed/update/...
EASD 2026 Final Overall Highlights | European Association for the Study of Diabetes e.V. (EASD)
🌍 One week. One global diabetes community. 16,000+ delegates! Thank you all for being part of #EASD2026! 🙏 From 28 September to 2 October, more than 16,000 registered delegates from around the world...
www.linkedin.com
October 3, 2026 at 9:16 AM
idfe.bsky.social
💙 What a week for our #KnowYourNumbers Mobile Unit at #EASD2026!

📍 300 health checks delivered to congress attendees and the public, supporting the launch of the first-ever #EUScreeningWeek. Making prevention more accessible and helping people understand their health numbers.
October 3, 2026 at 8:02 AM
practicaldiabetic.bsky.social
#EASD2026 : Almost 10k (6 miles per day) ;)
October 2, 2026 at 8:48 PM
practicaldiabetic.bsky.social
#EASD2026
October 2, 2026 at 4:23 PM
springermedicine.com
From #EASD2026 - Orforglipron, an oral non-peptide #GLP1 receptor agonist may be a feasible treatment option for patients with type 2 diabetes who are at increased cardiovascular risk.

Full story 👉️ buff.ly/TRkGkce

#MedNews
Oral orforglipron shows cardiovascular safety in patients with type 2 diabetes
Orforglipron, an oral non-peptide GLP-1 receptor agonist may be a feasible treatment option for patients with type 2 diabetes who are at increased cardiovascular risk.
springermedicine.com
October 2, 2026 at 3:15 PM
medpagetoday.com
Adults with type 2 diabetes achieved impressive weight loss with an investigational combination agent of eloralintide plus tirzepatide (Mounjaro, Zepbound), according to a phase IIb study. @easdnews.bsky.social #EASD2026
https://www.medpagetoday.com/meetingcoverage/easd/123239
Striking Weight Loss Seen With Combo Drug in Diabetes Trial
But more than one in four study participants quit trial due to adverse events
www.medpagetoday.com
October 2, 2026 at 2:25 PM
theisn.org
🌍 ISN was delighted to be at #EASD2026 in Milan represented by Maria José Soler presenting “Early combination therapy in diabetic kidney disease: Is the time to act now?”

A valuable opportunity to exchange knowledge and strengthen collaboration across specialties to advance kidney care worldwide.
October 2, 2026 at 2:19 PM
emjreviews.com
Could metabolic changes affect lung health before diabetes develops?

At the @easdnews.bsky.social 2026, higher glucose levels and lower insulin sensitivity were associated with reduced lung function in adults without diabetes or lung disease.

🔗: www.emjreviews.com/diabetes/new...

#EASD2026
Impaired Insulin Sensitivity Linked to Lung Function: EASD 2026
Lung function was reduced with higher glucose, lower insulin sensitivity and impaired insulin clearance in adults without diabetes.
www.emjreviews.com
October 2, 2026 at 1:29 PM
practicaldiabetic.bsky.social
That is a wrap for #EASD2026. Thank you to #dedoc⁰ for allowing me to come. I have just enough time to see Da Vinci's codex before heading to the airport and back to Australia.
October 2, 2026 at 12:56 PM
midgardfinance.com
💊 #pharma #EASD2026

🇺🇸 #$LLY #orforglipron on major heart events vs insulin: hazard ratio 0.77 (0.52-1.13). Too small a trial to prove a benefit.

Not head to head: tirzepatide 0.92 vs dulaglutide; 🇩🇰 #$NOVO #semaglutide pill 0.86, injection 0.80 vs placebo.

midgardfinance.com/cardiovascular/
Forest plot of hazard ratios for major heart events (heart attack, stroke or cardiovascular death) in four outcome trials of incretin drugs, on a log axis with a vertical line at 1; left of the line means fewer events than the comparison arm. The rows are in two groups because the trials were run against different things. Tested against placebo, in light blue: Semaglutide injection against placebo (SELECT, 17,604 patients): 0.80, interval 0.72 to 0.90. Semaglutide pill against placebo (SOUL, 9,650 patients): 0.86, interval 0.77 to 0.96. Tested against another drug, in purple: Tirzepatide against dulaglutide (SURPASS-CVOT, 13,299 patients): 0.92, interval 0.83 to 1.01. Orforglipron pill against insulin glargine (ACHIEVE-4, 2,749 patients): 0.77, interval 0.52 to 1.13. Orforglipron's estimate lies among the others, but its interval is about 4 times as wide and crosses 1: its trial was sized to rule out harm, which it did, not to prove a benefit. These are separate trials, not head-to-head comparisons. Dulaglutide is itself a heart-protective drug, so a ratio against it cannot be set beside a ratio against placebo, and SELECT enrolled people without diabetes while the other three enrolled people with type 2 diabetes. For orforglipron this is the three-part endpoint; its primary endpoint, which also counts hospitalisation for unstable angina, was 0.84 with an interval of 0.59 to 1.20.
October 2, 2026 at 12:30 PM
easdnews.bsky.social
🙏🇮🇹 Grazie, Milano! 🙏🇮🇹 Thank you, Milan!

#EASD2026 has come to a close. Thank you to our delegates, speakers, chairs, presenters, exhibitors, volunteers, organising teams, partners & collaborators for making this Annual Meeting possible.

And now…
🔔 🇭🇺 Save the date for #EASD2027 in Budapest!
October 2, 2026 at 12:25 PM